Guest guest Posted January 26, 2003 Report Share Posted January 26, 2003 http://www.breggin.com/resume.html Peter R. Breggin, M.D. 4628 Chestnut Street Bethesda, Maryland 20814 Telephone: (301) 652-5580 Fax: (301) 652-5924 ANNOTATED RESUME (follows one page summary) ONE-PAGE RESUME SUMMARY I. BACKGROUND HIGHLIGHTS: Harvard College (Cambridge) (1954-58) with Honors. Directed Harvard-Radcliffe Mental Hospital Volunteer Program. Research grants from Harvard Medical School and the National Institute of Mental Health (NIMH). Wrote first professional book. Case Western Reserve School of Medicine (Cleveland) (1958-1962). Conducted four years of psychopharmacology lab research with controlled animal trials. Research supported by NIMH grant. Special four-year tutorial with pediatrician Benjamin Spock, M.D. Massachusetts Mental Health Center (Boston) (1963-64). First Year Resident in Psychiatry at the main Harvard teaching hospital. Also, Teaching Fellow at Harvard Medical School. State University of New York Upstate Medical Center (Syracuse) (1962-63, 1964-66). Intern in Mixed Medicine and Psychiatry & Second and Third Year Resident in Psychiatry. Also, Teaching Assistant in Psychiatry. National Institute of Mental Health (NIMH) and U. S. Public Health Service Officer (Charlottesville, VA and Bethesda, MD) (1966-68). Full-time Consultant in Building and Staffing Mental Health Centers & in Mental Health and Education (1966-68). George Mason University (1990-96). Adjunct Professor of Conflict Analysis & Resolution. Johns Hopkins University (1996-99). Faculty Associate in the Department of Counseling and Human Services. II. HIGHLIGHTS OF CURRENT PROFESSIONAL ACTIVITIES: Private Practice of Psychiatry (Washington, DC and Bethesda, MD) (1968-present). Full-time private practice with individuals, families, and children. Subspecialty in adverse effects of psychiatric treatments and in medical-legal issues. Licensed in Washington, D.C., Maryland, Virginia and New York. Founder and Director, International Center for the Study of Psychiatry and Psychology (1972-present). Reform organization including former members of the U. S. Congress and more than a thousand membership. Publishes a peer-reviewed journal and a newsletter; holds national conferences. Editor-in-Chief and then Co-Editor, Ethical Human Sciences and Services: An International Journal of Critical Inquiry (peer reviewed) (1998-) with more than 50 top editorial board members. Editorial Board member of six peer-reviewed professional journals. Scientific Presenter. National Institutes of Health (NIH) Consensus Development Conferences on Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder (November 1998) and on Electroconvulsive Therapy (1985). Professional, state, and Congressional conferences and inquiries, including the U.S. House of Representatives Committee on Education (September 2000) about stimulants. Grand Rounds, Workshops, and Other Professional Presentations. Hundreds of presentations to professionals on psychopharmacology, shock treatment, psychosurgery, psychiatry, and legal issues. Advanced Training Courses in psychopharmacology, drug development, the FDA Medical Expert in many cases in past 25 years including criminal, malpractice, product liability and class action, often involving psychopharmacology, including neuroleptic-induced tardive dyskinesia. Provided scientific basis for the combined Prozac suits (1994) and the Ritalin class action suits (2000). Memberships: American Psychiatric Association (Life Member), American Orthopsychiatric Association (Fellow), Canadian Psychiatric Association, Royal Society of Medicine, Regulatory Affairs Professionals Society (RAPS), Drug Information Association (DIA). Publications: More than 14 professional books and more than 24 peer-reviewed journal articles. ANNOTATED RESUME Index: EDUCATIONAL BACKGROUND POST-TRAINING FULL-TIME CONSULTANT WITH NIMH SAMPLE OF PRIOR PROFESSIONAL ACTIVITIES CURRENT PROFESSIONAL ACTIVITIES PROFESSIONAL PRESENTATIONS TO GRAND ROUNDS AT HOSPITALS, WORKSHOPS, AND SEMINARS SPECIAL TRAINING COURSES PEER REVIEWER FOR PEER REVIEWED JOURNALS PROFESSIONAL PUBLICATIONS PROFESSIONAL AND GENERAL MEDIA COVERAGE OTHER DISTINCTIONS LICENSURE AND CERTIFICATION MISCELLANEOUS MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS This resume also serves as a history of my clinical, research, and reform work. I. EDUCATIONAL BACKGROUND HARVARD COLLEGE, B.A., Cambridge, Massachusetts, 1954-58 *Majored in Social Relations (combined psychology, sociology and anthropology). Graduated with honors in General Studies. Awarded Honorary Harvard Scholarship and Honorary John Harvard Scholarship. *Director, Harvard-Radcliffe Mental Hospital Volunteer Program for children and adults. Developed and led innovative case aide therapy program for severely disturbed state hospital patients. The program was sponsored by the Harvard Medical School Department of Psychiatry and was described as an important contribution to the future of psychiatry in the final report of the Congressionally-mandated Joint Commission on Mental Illness and Mental Health (1961). *Psychiatric research fellowship from the National Institute of Mental Health (NIMH). *Psychiatric research grant from Harvard Medical School. *Co-authored first professional book on the hospital volunteer program. *Assisted in controlled clinical trials in state hospital. *Editorial board, Harvard Crimson. CASE WESTERN RESERVE SCHOOL OF MEDICINE, Medical Degree, Cleveland, Ohio 1958-1962 *Research in psychopharmacology. Developed and conducted independent four year laboratory experimental study in the psychophysiology and psychopharmacology of anxiety with controlled trials using epinephrine administered to animals. *NIMH research grant to sponsor the research project. *Authored first two peer reviewed journal articles on psychophysiology and psychopharmacology. *Four year individual clinical tutorial in pediatrics and family health with pediatrician Benjamin Spock. STATE UNIVERSITY OF NEW YORK, INTERNSHIP, MIXED MEDICINE AND PSYCHIATRY, Upstate Medical Center, Syracuse, New York, 1962-63 MASSACHUSETTS MENTAL HEALTH CENTER (the main training facility of Harvard Medical School), FIRST YEAR RESIDENT IN PSYCHIATRY, Boston, Massachusetts, 1963-64 *Teaching Fellow, Harvard Medical School. STATE UNIVERSITY OF NEW YORK, SECOND AND THIRD YEAR RESIDENT IN PSYCHIATRY, New York Upstate Medical Center, 1964-66 *Teaching Assistant in Psychiatry. II. POST-TRAINING FULL-TIME CONSULTANT WITH NIMH Following completion of my medical and psychiatric training, I entered the U. S. Public Health Service as a medical officer with the rank of Surgeon (Full), the equivalent of a Lt. Cmdr. I was assigned to the National Institute of Mental Health (NIMH). This was a highly sought after professional position. NATIONAL INSTITUTE OF MENTAL HEALTH, FULL-TIME CONSULTANT IN BUILDING AND STAFFING MENTAL HEALTH CENTERS, Region III, Charlottesville, Virginia, 1966-67. *Consulted with communities to establish mental health centers under federal guidelines. *Evaluated mental hospital programs in region. NATIONAL INSTITUTE OF MENTAL HEALTH, FULL-TIME CONSULTANT IN MENTAL HEALTH AND EDUCATION, Bethesda, Maryland, 1967-68. *Evaluated and developed programs for children and youth. *Evaluated applications for research funding. Following the completion of two years at NIMH in 1968, I went into private practice, consulting, and teaching in the Washington, D.C. metropolitan area. I have continued with these and related activities in this community for the past 31 years. III. SAMPLE OF PRIOR PROFESSIONAL ACTIVITIES INVITED REPORT ON " PRINCIPLES FOR THE ELIMINATION OF RESTRAINT " FOR THE JOINT COMMISSION ON ACCREDITATION OF HEALTH CARE ORGANIZATIONS (JCAHCO) filed April 25, 1999. INVITED SCIENTIFIC PRESENTER ON " STIMULANT DRUGS: ADVERSE REACTIONS AND MECHANISM OF ACTION " AT THE NIH CONSENSUS DEVELOPMENT CONFERENCE ON DIAGNOSIS AND TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER, National Institutes of Health, Bethesda, MD November 1998 INVITED PROFESSIONAL PRESENTER ON " ATTENTION DEFICIT HYPERACTIVITY DISORDER AND STIMULANT MEDICATION " TO THE STATE OF MARYLAND LEGISLATIVE TASK FORCE TO STUDY THE USE OF METHYLPHENIDATE AND OTHER DRUGS ON SCHOOL AGE CHILDREN, Maryland Department of Health and Mental Hygiene, Baltimore MD May 29, 1998 JOHNS HOPKINS UNIVERSITY, DEPARTMENT OF COUNSELING AND HUMAN SERVICES, FACULTY ASSOCIATE, Baltimore, MD 1996-Jan 1999 *Instructor in varied subjects, including Diagnosis and Treatment (including medication), Post-traumatic Stress Disorder, Counseling and Psychotherapy in Community Facilities, and Critical Issues in Mental Health. GEORGE MASON UNIVERSITY, PROFESSOR (Adjunct) OF CONFLICT ANALYSIS AND RESOLUTION, INSTITUTE FOR CONFLICT ANALYSIS AND RESOLUTION, Fairfax, VA 1990-96 *Instructor in seminars for graduate students. Subjected includes included Brain, Mind and Behavior, and Domestic Violence and Child Abuse MARYMOUNT UNIVERSITY, DEPARTMENT OF PSYCHOLOGY, INTERNSHIP COORDINATOR, Arlington, VA 1997-98 Supervise and instruct undergraduate and graduate interns placed at the Center for the Study of Psychiatry and Psychology. Topics include psychiatric medication and how to conduct research. Interns from Marymount University (graduate and undergraduate psychology students) and from the Johns Hopkins University School of Public Health. AMERICAN ACADEMY OF PSYCHOTHERAPISTS, ADVISOR TO THE RESEARCH COMMITTEE, Washington, DC 1993-1996 PSYCHIATRIC INSTITUTE OF D.C. AND SUBURBAN HOSPITAL, ADMITTING PRIVILEGES, early to mid-1970s. *I allowed my privileges to lapse since I so seldom have the need to hospitalize my patients. WASHINGTON SCHOOL OF PSYCHIATRY, FACULTY, Washington, D.C., 1968-1972. *Director, Project to Examine Psychiatric Technology. Developed critiques of psychosurgery and electroshock treatment. *Consultant, District of Columbia Pupil Personnel Services. *Taught seminars for professionals. UNIVERSITY OF MARYLAND, DEPARTMENT OF COUNSELING, SCHOOL OF EDUCATION, CONSULTANT, College Park, MD 1968-70 ANTIOCH-PUTNEY GRADUATE SCHOOL OF EDUCATION, CONSULTANT, Washington, DC, 1968-70 IV. CURRENT PROFESSIONAL ACTIVITIES FULL-TIME PRIVATE PRACTICE OF PSYCHIATRY, 1968-present, in Bethesda, Maryland and the Washington, DC, metropolitan area. Thirty years experience in private practice: *Psychotherapy for individuals, couples, and families, including children. *Subspecialty in the adverse effects of medications, electroshock, and psychosurgery. *Subspecialty in forensic psychiatry and patient rights. EDITOR-IN-CHIEF and then CO-EDITOR, ETHICAL HUMAN SCIENCES AND SERVICES: AN INTERNATIONAL JOURNAL OF CRITICAL INQUIRY, 1998-present (a peer review professional journal, first issue May 1999). The senior editors and the 50 member Editorial Advisory Board are drawn from around the world in fields such as psychiatry, psychology, counseling, education, public health, neuropharmacology, and cellular toxicology. They include professors; directors of hospitals, academic departments, and clinics; editors-in-chief of professional journals; and internationally known clinicians, researchers, and authors. FOUNDER AND DIRECTOR, INTERNATIONAL CENTER FOR THE STUDY OF PSYCHIATRY AND PSYCHOLOGY, Bethesda, Maryland, 1972-present Activities include an international conference alternating between the USA and UK, an international peer reviewed journal, newsletter, web site, and general membership. The Center has several North American regional divisions and centers in Great Britain and Australia. The Board of Directors and Advisory Council network consists of nearly 200 individuals includes psychiatrists, psychologists, counselors, social workers, drug researchers, and patient rights advocates. They include members of the U. S. Congress; professors; directors of hospitals, academic departments, and clinics; journal editors, and respected clinicians and researchers. Hundreds of additional professionals and laypersons belong to the general membership. The Center sends information packages in response to thousands of inquiries each year from professionals, the public, and the media--often concerning medications and adverse medication effects. Center accomplishments span more than twenty-five years, including: *Stopping the wide-scale resurgence of lobotomy and psychosurgery on adults and children, and the stopping of all known psychosurgery on children and all psychosurgery in federal and state institutions (1970s). *The creation of the federal Psychosurgery Commission by Congress (1970s). *Alerting the profession to the danger of tardive dyskinesia in children (1983). Tardive dyskinesia is a potentially devastating neurological disorder caused by neuroleptic or antipsychotic drugs. *Alerting the profession to the danger of dementia produced by longer-term use of neuroleptic drugs (1983). *Causing the FDA to force the drug companies to put in their labels for neuroleptic drugs a new class warning on tardive dyskinesia (1985). *The withdrawal of a large multi-agency federal program to perform dangerous invasive experiments on inner-city children in search of supposed genetic and biochemical causes of violence (the violence initiative) (early 1990s). *The initial cancellation and later modification of a potentially racist federally sponsored conference on the genetics of violence (early 1990s). *Exposing the channeling of drug company funds to individual researchers at NIH through the intermediary foundation, FAES, leading to cancellation of this program, circa 1994. *Alerting the profession to danger of down-regulation and dangerous withdrawal reactions from the new SSRI antidepressants, such as Prozac, Zoloft, and Paxil (1992-4). *Alerting the profession and the public to the flawed nature of controlled clinical trials in determining efficacy and safety (1994, Talking Back to Prozac). Now many the problems are generally recognized. *Developing the scientific basis for all of the combined Prozac product liability cases against Eli Lilly & Co. Dozens of these cases have been quietly settled by the drug company. Only one of my cases has gone to court (Fentress v., in Louisville, Kentucky, the " Wesbecker Case " ). I provided much of the background research and testified as a expert in psychiatry and the FDA drug approval process. The suit was secretly settled during trial without informing the judge. The plaintiffs accepted a huge settlement in return for providing the jury with a weakened presentation of the case against the defendant drug company. The jury found for the defendants by a 9-3 vote. Afterward, the Supreme Court of Kentucky found in regard to Eli Lilly, " In this case, there was a serious lack of candor with the trial court and there may have been deception, bad faith conduct, abuse of the judicial process and perhaps even fraud. " The trial judge, John Potter, was empowered to change the jury verdict to " settled with prejudice " against Lilly. *Monitoring and at times modifying or stopping unethical, hazardous experimental research on children (1973 to the present). *Criticism of the supposed biological basis of ADHD and the analysis of potentially damaging effects of stimulant medication. Following my scientific testimony, many of my views and concerns were confirmed by the final report of the NIH Consensus Development Conference on The Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder in November 1998. *Criticism of the escalating tendency to give psychiatric drugs to preschoolers. Our center was the first to raise this issue. In 1998 we informed the International Narcotics Control Board about the drugging of children as young as two; the World Health Organization agency then issued a warning about it. In Talking Back to Ritalin (1998) I made one the first analyses of the dangers of these drugs in young children. More recently, a report and an editorial in the Journal of the American Medical Association confirmed the gravity of the problem. In March 2000 in response to public outcry raised partly in response to our national educational efforts, the White House (Hillary Clinton) made a public statement showing concern about the medicating of preschoolers. *Inspired and provided medical consultation on the original Ritalin Class Action Suit. The model Ritalin class action suit against the manufacturer, Novartis, as well as CHADD and the American Psychiatric Association, was brought by C. Andrew Waters of Dallas, Texas in 2001, based on Talking Back to Ritalin and other publications by Peter Breggin and in consultation with him. Multiple suits have been brought since then. While each of these critiques and reform projects was initially considered highly controversial, and while each was frequently opposed by organized psychiatry, most are now accepted as rational and ethical by medicine in general. For example, psychosurgery is no longer widely practiced and not at all in state or federal institutions or on children in the United States; the multi-agency federal research program aimed at using invasive procedures on inner-city child has been disbanded; the conference on the genetics of violence was delayed and then vastly modified; all experts now recognize the dangers of tardive dyskinesia in children; many researchers have confirmed that the neuroleptic drugs produce dementia; experienced doctors now recognize the potential for dangerous withdrawal effects from the SSRIs; and the controversy surrounding ADHD and stimulant medication has been confirmed by the NIH Consensus Development Conference. FORENSIC ACTIVITIES AS A MEDICAL AND PSYCHIATRIC EXPERT Psychiatric and medical expert in county, state, and federal courts with trial testimony in approximately 40 cases in thirty years, including civil and criminal suits involving psychopharmacology, FDA regulations, and product liability. In 1973, for example, I testified in Kaimowitz v. Department of Mental Health, leading to a three-judge decision that ultimately stopped experimental psychosurgery in state and federal facilities throughout the United States. In the past ten years, testimony in more than 25 court proceedings, including malpractice suits, criminal cases, and two product liability cases. I testified as the medical expert in the first criminal case in Virginia (Commonwealth v. Khaliqi, 1997) in which a judge dismissed criminal assault charges on the grounds of involuntary intoxication with psychiatric drugs. My expertise was acknowledged in two product liability cases against drug companies in Fentress v. Eli Lilly (1994) (the " Wesbecker " Case) involving Prozac as a possible cause of murderous and suicidal behavior [settled in trial], and in Mitchell v. Upjohn (1998) involving addiction to Xanax. My book, Talking Back to Ritalin, provided the basis for the multiple class action suits now being brought against the manufacturer of Ritalin, Novartis, and I consulted as the medical expert for the prototype case brought in Dallas, Texas. As a part of my forensic and research work, I frequently review the federal statutes and regulations governing the FDA, research standards, drug research, and the drug approval process. I have reviewed many New Drug Applications (NDAs) for psychiatric medications, including reviews of entire NDAs at the home-office of pharmaceutical firms as a part of the discovery process in product liability cases. SAN JOAQUIN PSYCHOTHERAPY CENTER, PSYCHIATRIC CONSULTANT, Clovis, CA, 1992-present V. PROFESSIONAL PRESENTATIONS TO GRAND ROUNDS AT HOSPITALS, WORKSHOPS, AND SEMINARS I frequently give grand rounds, seminars, and full day workshops for professionals and students, and often participate on professional panels. Subjects include psychiatric treatment, including electroshock, medication and medication side effects. The following is a sample: *Invited Scientific Presentations to NIH Consensus Conferences Scientific presenter on the adverse effects of psychiatric drugs in children at the November 1998 NIH Consensus Development Conference on " The Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder. " Scientific presenter on cognitive deficits and brain damage and dysfunction caused by electroshock treatment at the1985 NIH Consensus Development Conference on " Electroconvulsive Therapy " *Presentations at Annual Conferences American Psychiatric Association (twice) American Psychiatric Association Institute on Hospital and Community Psychiatry American Psychological Association (many times), New Jersey Psychological Association, Maryland Psychological Association, and many others. American Orthopsychiatry Association (several times) American Autism Society American Association for the Advancement of Science American Counseling Association (many times), District of Columbia Counseling Association (several times), Maryland Association for Counseling and Development, 48th Annual West Virginia Counseling Association Conferences, and others. Association for the Advancement of Behavioral Therapy International Symposium for the Psychotherapy of Schizophrenia International Association of Psychosocial Rehabilitation Services International Association of Biblical Counselors National Association for Rights Protection and Advocacy (NARPA) (many times) National Center on Institutions and Alternatives: Reaffirming Rehabilitation. NIMH Community Support Program National Conference Southern Christian Services for Children and Youth North American Society of Adlerian Psychology Canadian Association for Reality Therapy, Annual International Convention, Ottawa. *Presentations to Medical Schools, Hospitals, Departments of Psychiatry and Professional Institutes or Agencies National Institutes of Health (NIH), Scientific Presenter on " Adverse Effects and Mechanism of Action of Stimulants " at the 1998 Consensus Development Conference on the Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder. National Institutes of Health & National Institute of Mental Health (NIMH), Scientific Presenter on " Neuropathology and Cognitive Dysfunction from ECT " at the 1985 Consensus Development Conference on Electroconvulsive Therapy. National Institutes of Health, Scientific Presenter to the 1994 Panel on NIH Research on Anti-social, Aggressive and Violence-related Behaviors and Their Consequences. National Institute of Mental Health Guest Speakers Program Harvard University School of Education Special Lecture Georgetown University School of Medicine, Department of Pharmacology (several times) New Jersey Medical School Department of Psychiatry Annual Medical Forum Walter Reed Army Hospital Psychiatric Residency Program (several times) University of Sheffield Department of Psychiatry (England) Royal Ottawa Hospital Grand Rounds (Canada) MIND of Great Britain Regents College of Psychotherapy and Counseling (London) Institute for Genetics (Cologne) Manhattan State Hospital (New York City) Grand Rounds Spring Grove Hospital (Maryland) CME Credit Seminars (several times) Chestnut Lodge Hospital (Maryland) Case Conference St. Elizabeths Hospital Grand Rounds and Seminars (Washington, DC) (several times) Suburban Hospital (Maryland) Grand Rounds Brooklane Psychiatric Hospital (Maryland) Annual Dinner District of Columbia Child and Family Services Johns Hopkins University Department of Counseling and Human Services Honor Society Lecture Metropolitan Hospital Center/New York Medical College Department of Psychiatry Illinois School of Professional Psychology American Society of Psychoanalytic Physicians (Washington, D.C.) Columbia University School of Journalism Harvard College Student Pugwash Society Maryland Association for Multi-cultural Counseling Bowie State University (several times) including In-service Training for Professors Maryland State Task Force to Study the Uses of Methylphenidate and Other Drugs on School Children Alta Bates Medical Center (Berkeley) CME credit Grand Rounds Springfield Hospital Center (Maryland) CME credit Grand Grounds Family Therapy Networker (Washington, DC) Veterans Administration Medical Center (Baltimore) *Workshops Given to Legal Organizations D.C. Bar Association (on neuroleptic drugs) Common Pleas Court of Clarion County, PA, sponsored by Judge Charles Alexander (on ADHD and stimulant drugs) American Conference Institute on " Ritalin Litigation " (special workshop and plenary on ADHD and stimulant drugs) (New York, 2001). Mealey's Emerging Drug Litigation Conference (plenary on ADHD and stimulant drugs) (New Orleans, 2001) *Presentations and Testimony before Government Agencies NIMH Consensus Development Conference on Electroconvulsive Therapy Food and Drug Administration (FDA) Hearing on ECT National Institute of Mental Health (NIMH) National Institute of Health (NIH) National Institute of Neurological Disease and Stroke U. S. Congress (several times) (Committees of the House and Senate, including Health) Most recently, by invitation at the hearing on " Behavioral Drugs in Schools: Questions and Concerns " of the Subcommittee on Oversight and Investigations and the Subcommittee on Early Childhood, Youth, and Families of the U.S. House or Representatives Committee on Education and the Workforce, September 29, 2000. State and City Legislative Committees and Councils many times have invited me to offer testimony, including most recently: 1. Colorado House of Representatives " Ad Hoc Committee on the role of Psychiatric Medication in Violence in School Shootings " (November 9, 1999, in person). 2. Arkansas House & Senate Subcommittee on Health Services of the House and Senate Committees on Public Health, Welfare and Labor on " Violence as related to the use of prescription/controlled drugs and the impact of prescription drug use on school violence " (May 3, 2000, in person). 3. Vermont Legislature " ECT [electroconvulsive therapy] Study Committee " (July 17, 2000, by telephone). 4. Nevada State Assembly Committee on Education concerning schools forcing parents to medicate their children (March 13, 2001, by direct consultation and letter). VI. SPECIAL TRAINING COURSES I continue to take courses that update my expertise in medication, adverse medication effects, the FDA, and the drug approval process, including the following special training seminars: " Psychopharmacology in Practice: Clinical and Research Update. " A course by the Foundation for advanced Education in the Sciences (National Institutes of Health). October 9-10, 1987. " Regulatory Training Course I: IND [investigative New Drug] Phase. " A course in how drug companies develop an IND for the FDA in accordance with FDA statutes, regulations, and guidelines. DIA (Drug Information Association). Bethesda, Maryland, February 26-28, 1996 " Regulatory Training Course II: Marketing Application & Post Approval Phase. " A course in how drug companies develop an NDA [New Drug Application], as well as post-approval activities, in accordance with FDA statutes, regulations, and guidelines. DIA (Drug Information Association), Bethesda, Maryland, March 27-29, 1996 " Clinical Therapeutics and the Recognition of Drug-Induced Disease: How Health Care Professionals and the FDA Can Work Together to Reduce the Risks of Adverse Drug Events. " A workshop focused on the spontaneous reporting system presented by the Center for Drug Evaluation and Research (CDER) of the FDA, Georgetown University School of Medicine, Washington DC, June 10, 1994 " The Application of GCP [Good Clinical Practices] for Study Site Coordinators and Business Administrators. " Described as " a comprehensive, practical overview of the responsibilities of the investigator, the clinical study coordinator assisting the investigator, and the sponsor in the conduct of a clinical trial " for FDA approval of a drug. DIA (Drug Information Association), Philadelphia, December 11-13, 1995 " Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder. " A three day conference on the latest concepts concerning ADHD and its treatment. I attended and was also a scientific presenter on the adverse effects of stimulant drugs. National Institutes of Health Consensus Development Conference, Bethesda, MD, November 16-18, 1998. " Pharmaceutical Industry Crisis Management Workshop. " Purpose described as " to develop the participants knowledge of the fundamental elements of crises and crisis management in the pharmaceutical industry. " Initial day covered handling of a variety of issues, including New Drug Applications (NDAs), FDA regulations and industry relations, recalls, adverse drug event reporting, and clinical trial standards. DIA (Drug Information Association), Washington, DC, December 4, 2000. " Ritalin Litigation. " Described as " The medical and legal roadmap to trying or defending your Ritalin suit successfully, " including presentations on stimulant drug treatment, ADHD, and the role of the FDA and DEA in monitoring industry activities. I attended and was also a presenter on " The science behind the lawsuits. " The American Conference Institute, New York City, March 29, 2001. " Emerging Drug Litigation Conference. " One-half day on class action suits, " The Science and Medicine of Ritalin " (my presentation), and Update and Strategies for Ritalin litigation. Mealey's (Lexis/Nexis) . New Orleans, May 17, 2001. VII. PEER REVIEWER FOR PEER REVIEWED JOURNALS In addition to being an editor-in-chief of a peer reviewed journal, I am on the editorial and review boards of several other peer reviewed journals, including journals that publish articles concerning the central nervous system, treatment, and treatment side effects. A. Current Journal Affiliations Editorial Board, Risk and Safety in Medicine Editorial Board, The Psychotherapy Patient Editorial Board, Changes: An International Journal of Psychology and Psychotherapy Consulting Editor, The Humanistic Psychologist Assessing Editor, Journal of Mind and Behavior B. Prior Journal Affiliations Special Editor (one issue), Journal of African American Men Reviewer, American Psychiatric Association Journal of Hospital and Community Psychiatry VIII. PROFESSIONAL PUBLICATIONS My bibliography includes the following: (1) 14-plus professional books, (2) More than two dozen peer-reviewed articles, (3) Numerous other professional publications, such as articles, reviews, letters, and book chapters. My publications cover the fields of psychiatry, psychopharmacology, neuroscience, and drug approval and regulation. The following publications are particularly focused on treatment, psychopharmacology, and adverse drug effects. For a more complete list, see my professional bibliography. A. PROFESSIONAL BOOKS 1. College Students in a Mental Hospital: Contribution to the Social Rehabilitation of the Mentally Ill (New York, Grune & Stratton, 1962) (jointly authored by Carter Umbarger, James Dalsimer, Andrew Morrison, and Peter Breggin). 2. Electroshock: Its Brain-Disabling Effects (Springer, NY, 1979) 3. The Psychology of Freedom: Liberty and Love as a Way of Life Buffalo, Prometheus Books, 1980. 4. Psychiatric Drugs: Hazards to the Brain (Springer, NY, 1983) 5. Toxic Psychiatry (St. Martin's, NY, 1991) 6. Beyond Conflict (St. Martin's, NY, 1992) 7. Talking Back to Prozac (with Ginger Breggin) (St. Martin's, NY, 1994) 8. The War Against Children (with Ginger Breggin) (St. Martin's, NY, 1994) 9. Psychosocial Approaches to Deeply Disturbed Persons (senior editor) (Haworth Press, NY, 1996) 10. Brain-Disabling Treatments in Psychiatry: Drugs, Electroshock and the Role of the FDA (Springer, NY, 1997) 11. The Heart of Being Helpful: Empathy and the Creation of a Healing Presence (Springer, NY, 1997) 12. Talking Back To Ritalin (Common Courage Press, ME, 1998) 13. The War Against Children of Color: Psychiatry Targets Inner City Children. (Common Courage Press, ME, 1998) (with G. Breggin) Revision and update of The War Against Children. 14. Your Drug May Be Your Problem: How and Why To Stop Taking Psychiatric Medications. (Perseus Books, Reading, MA, 1999) (Co-authored by David Cohen, Ph.D.) 15. Reclaiming Our Children: A Healing Solution to a Nation in Crisis. (Perseus Books, Reading, MA, 2,000) 16. Empathic Turning Points in Therapy (jointly co-edited by Ginger Breggin and Fred Bemak) (Springer, NY, in progress, circa 2001) B. SAMPLE OF PEER REVIEWED JOURNALS IN WHICH ARTICLES PUBLISHED Psychopharmacology Bulletin Journal of Mind and Behavior Journal of Nervous and Mental Disease Archives of General Psychiatry Psychiatric Quarterly Psychiatry American Journal of Psychotherapy Mental Health and Society International Journal of Risk & Safety in Medicine Changes: An International Journal of Psychology and Psychotherapy Review of Existential Psychiatry and Psychology Brain and Cognition Behavior and Brain Sciences (commentary) Voices: Journal of the American Academy of Psychotherapy Journal of College Student Psychotherapy The Humanistic Psychologist C. SAMPLE OF PEER-REVIEWED JOURNAL PUBLICATIONS " What psychologists and psychotherapists need to know about ADHD and stimulants. " Changes: An International Journal of Psychology and Psychotherapy 18:13-23, Spring 2000 " The NIMH multimodal study of treatment for attention-deficit/hyperactivity disorder: A critical analysis. " International Journal of Risk and Safety in Medicine, 13:15-22, 2000. " Psychostimulants in the treatment of children diagnosed with ADHD: Risks and mechanism of action. " International Journal of Risk and Safety in Medicine 12:3-35, 1999. (Simultaneous publication of same report published in two parts in Ethical Human Sciences and Services; see below) " Psychostimulants in the treatment of children diagnosed with ADHD: Part I: Acute risks and psychological effects. " Ethical Human Sciences and Service 1:13-33, 1999. “Psychostimulants in the treatment of children diagnosed with ADHD: Part II: Adverse effects on brain and behavior.” Ethical Human Sciences and Services 1:213-242, 1999. " Psychotherapy in emotional crises without resort to psychiatric medication. " The Humanistic Psychologist 25:2-14, 1998. " Electroshock: scientific, ethical, and political issues. " International Journal of Risk & Safety in Medicine 11:5-40, 1998. " Analysis of adverse behavioral effects of benzodiazepines with a discussion of drawing scientific conclusions from the FDA's Spontaneous Reporting System. " Journal of Mind and Behavior 19: 21-50, 1998. " The hazards of treating 'attention-deficit/hyperactivity disorder' with methylphenidate (Ritalin) " (with G. Breggin) Journal of College Student Psychotherapy 10:55-72, 1996. " Should the use of neuroleptics be severely limited? " Changes: An International Journal of Psychology and Psychotherapy 14:62-66 March 1996. " Parallels between neuroleptic effects and lethargic encephalitis: The production of dyskinesias and cognitive disorders. " Brain and Cognition 23:8-27, 1993. " A case of fluoxetine-induced stimulant side effects with suicidal ideation associated with a possible withdrawal syndrome ( " Crashing " ). " International Journal of Risk & Safety in Medicine 3:325-328, 1992 " Brain damage, dementia and persistent cognitive dysfunction associated with neuroleptic drugs: evidence, etiology, implications. " Journal of Mind Behavior 11:425-464, 1990. " Ellettroshock: Tra rischioiatrogeno e mito terapeutico. " (co-authored: P. Breggin and G. de Girolamo) Quaderni Italiani di Psychiatrica 6:497-540, 1987. " Neuropathology and cognitive dysfunction from ECT. " Psychopharmacology Bulletin 22:476-479, 1986. " Electroshock therapy and brain damage: the acute organic brain syndrome as treatment. " Behavior and Brain Sciences 7:24-25, 1984 (commentary). " The sedative-like effect of epinephrine. " Archives of General Psychiatry 12:255-259, 1965. " The psychophysiology of anxiety. " Journal of Nervous Mental Diseases 139:558-568, 1964. IX. PROFESSIONAL AND GENERAL MEDIA COVERAGE My views and reform efforts have been covered in leading professional sources, such as the Journal of the American Medical Association, Science, Nature, American Journal of Psychiatry, Psychiatric News, Clinical Psychiatry News, Science News, Psychology Today, and the Chronicle of Higher Education. My work has also been covered many times leading public media, such as the New York Times, Washington Post, USA Today, Time, and Newsweek. I have also appeared as an expert on almost all the major electronic media, often many times, including programs such as " Nightline, " " 20/20, " " 60 Minutes, " " Dan Rather Reports, " " Larry King Live, " and " Oprah. " X. OTHER DISTINCTIONS Hewlett-Woodmere Alumni Association Hall of Fame (2001) Certificate of Special Congressional Recognition " in recognition of outstanding and invaluable service to the community " in psychiatry (2001). Carolyn McCarthy, Member of Congress. ICSPP Century Achievement Award (2000) Dr. Ephraim T. Lisansky Lecture at the University of Maryland School of Social Work (2000) Maryland Association for Multicultural Counseling and Development, and the Bowie State University Department of Education Certificate of Distinction (2000) Great Minds in Counseling Lecture Series of George Washington University (1997) The 1999 Gustavus Myers Outstanding Book Award Honorable Mention for The War Against Children of Color. The 1998 NARPA Johnson Award " For Lifetime Contributions to the Field of Mental Health Advocacy. " Presented by the National Association for Rights Protection and Advocacy (NARPA) at the annual meeting. The 1990 Minnesota Mental Health Association, David J. Vail National Advocacy Award " For distinguished service in protecting the rights and dignity of mentally disabled Americans. " The 1987 Ludwig von Mises Award of Merit for efforts on behalf of the rights of psychiatric patients. Who's Who in America, 1973-present International Who's Who, 1998-present Honorary Visiting Fellow, Regents College School of Psychotherapy and Counseling, London, England, 1994 XI. LICENSURE AND CERTIFICATION Licensed to practice medicine in Maryland, Virginia, Washington DC, and New York Diplomate, National Board of Medical Examiners (99.9 percentile in psychiatry) Identified as a " Specialist in Psychiatry " by the State of Maryland, Department of Mental Health and Hygiene, Board of Physician Quality Assurance Diplomate of the American Board of Forensic Medicine, Specialty: Malpractice, Product Liability, and Criminal Responsibility; and Fellow of the American College of Forensic Examiners XII. MISCELLANEOUS Dissertation reader, Saybrook Graduate School, San Francisco Advisory Board, Institute for the Study of Academic Racism (ISAR) XIII. MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS *Medical, Psychiatric and Psychological Associations Royal Society of Medicine (Great Britain): Elected Member, Sections on Psychiatry, Neurology, and Paediatrics Life Member, American Psychiatric Association Fellow, American Orthopsychiatric Association Canadian Psychiatric Association: Sections on Psychopharmacology, Neuropsychiatry, Forensic Psychiatry, and Child & Adolescent Psychiatry & Mental Retardation American Psychological Association (by special election): Division of Psychopharmacology and Substance Abuse, and Division of Humanistic Psychology American Counseling Association American Association for the Advancement of Science (AAAS) Foundation for Advanced Education in the Sciences (FAES) at the National Institutes of Health Washington Psychiatric Society National Association for Rights Protection and Advocacy (NARPA) *Organizations that Focus on the Pharmaceutical Industry, the FDA, and the Drug Approval Process. Drug Information Association (DIA) Regulatory Affairs Professionals Society (RAPS) Gettingwell- / Vitamins, Herbs, Aminos, etc. To , e-mail to: Gettingwell- Or, go to our group site: Gettingwell Mail Plus - Powerful. Affordable. Sign up now Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.